MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Buys 46,620 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 46,620 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average price of $1.35 per share, with a total value of $62,937.00. Following the completion of the transaction, the director directly owned 735,701 shares of the company’s stock, valued at $993,196.35. This represents a 6.77% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The stock was purchased at an average cost of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.39 per share, with a total value of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Price Performance

Shares of MAIA Biotechnology stock opened at $1.30 on Wednesday. The stock’s 50 day simple moving average is $1.37 and its 200-day simple moving average is $1.43. The stock has a market cap of $79.08 million, a P/E ratio of -2.10 and a beta of 0.25. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts expect that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Trading of MAIA Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MAIA. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the 2nd quarter worth about $29,000. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at $52,000. PVG Asset Management Corp acquired a new stake in MAIA Biotechnology in the first quarter valued at $46,000. Susquehanna International Group LLP acquired a new stake in MAIA Biotechnology in the second quarter valued at $51,000. Finally, Corsair Capital Management L.P. acquired a new position in shares of MAIA Biotechnology during the 1st quarter worth about $140,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.